Evidence map›Paper›PMID 27371576›Full record

ArticleCancer discovery2016

An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation.

Sebastian T Balbach, Stuart H Orkin

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Loss-of-function mutations of microRNA-142-3p promoteWorld journal of gastroenterology · 2025
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Sebastian T BalbachDana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Stuart H OrkinDana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. Harvard Stem Cell Institute, Cambridge, Massachusetts. Howard Hughes Medical Institute, Boston, Massachusetts. Stuart_Orkin@dfci.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone H3 lysine 36 dimethylation (H3K36me2), a modification associated with transcriptional activation, is required for mixed-lineage leukemia-dependent transcription and leukemic transformation. In this issue of Cancer Discovery, Zhu and colleagues map the network of readers, writers, and erasers of H3K36me2 and uncover the ASH1L histone methyltransferase as a novel target for therapeutic intervention. Cancer Discov; 6(7); 700-2. ©2016 AACR.See related article by Zhu and colleagues, p. 770.

Indexed as

Translocation, GeneticDNA-Binding ProteinsEpigenesis, GeneticGene Expression Regulation, LeukemicHematopoiesisHistone-Lysine N-MethyltransferaseHistonesHumansLeukemiaLysineMethylationMyeloid-Lymphoid Leukemia ProteinTranscription FactorsASH1L protein, humanDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseHistonesLysineMyeloid-Lymphoid Leukemia ProteinTranscription Factors

Identifiers

PMID27371576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.